Angiogenesis Inhibitors And Stimulators Market Drivers, Trends, and Forecast by 2031

MARKET INTRODUCTION

Angiogenesis is a physiological process associated with the formation of the new blood vessel from existing blood vessels. The angiogenesis process is commonly categorized into two types, namely sprouting angiogenesis and intussusceptive angiogenesis. Sprouting angiogenesis is a fundamental vessel growth mechanism in which sequential steps regulate the new blood vessel's formation. Intussusceptive angiogenesis (also called splitting angiogenesis) is referred to as the new blood vessel created by the internal division of an existing blood vessel. Angiogenesis is mainly associated with a diverse set of conditions such as age-related macular degradation, rheumatoid arthritis, cancer, and psoriasis. The main focus of angiogenesis therapy is to shrink the existing tumor by an inhibitor or to meet the demand of under perfused region through generating new vessels by angiogenesis stimulator. Avastin (bevacizumab), Gleevec, Tarceva, and Iressa are some of the most extensive selling angiogenesis inhibitors worldwide.

MARKET DYNAMICS

The increase in the prevalence of cancer and recognition of therapeutic opportunities offered by oncology treatments and increasing investments in research and development will spur the demand for angiogenesis inhibitors and stimulators market. Additionally, technological advancement and increase in awareness, use of angiogenesis inhibitors in treatment of variety of indications will boost the market growth to significant extent over the forecast period. However, stringent government regulations and high cost of treatment impede the growth of the market in the forecasted period.

MARKET SCOPE

The "Global Angiogenesis Inhibitors and Stimulators Market Analysis to 2031" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of angiogenesis inhibitors and stimulators market with detailed market segmentation by product, application and geography. The global angiogenesis inhibitors and stimulators market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading angiogenesis inhibitors and stimulators market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global angiogenesis inhibitors and stimulators market is segmented on the product, and applications. Based on product, the global angiogenesis inhibitors and stimulators market is segmented into sprouting angiogenesis, and intussusceptive angiogenesis. Based on application, the global angiogenesis inhibitors and stimulators market is segmented into hospitals, clinics, and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global angiogenesis inhibitors and stimulators market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The angiogenesis inhibitors and stimulators market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting angiogenesis inhibitors and stimulators market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Angiogenesis inhibitors and stimulators market in these regions.

MARKET PLAYERS

The reports cover key developments in the angiogenesis inhibitors and stimulators market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from angiogenesis inhibitors and stimulators market are anticipated to lucrative growth opportunities in the future with the rising demand for angiogenesis inhibitors and stimulators market in the global market. Below mentioned is the list of few companies engaged in the angiogenesis inhibitors and stimulators market.

The report also includes the profiles of key angiogenesis inhibitors and stimulators market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

•   F. Hoffmann-La Roche Ltd
  
•   Abbott
  
•   Bristol-Myers Squibb Company
  
•   Amgen Inc
  
•   AstraZeneca
  
•   Novartis AG
  
•   CASI Pharmaceuticals Inc.
  
•   EYETECH DIGITAL SYSTEMS
  
•   Johns Hopkins Medicine
  
•   Pfizer Inc
  

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Angiogenesis Inhibitors And Stimulators Report Scope